시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 화학요법 유발 메스꺼움 및 구토(CINV) 시장 보고서(2025년)
Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2025
상품코드 : 1824610
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,498,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,393,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,288,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 화학요법 유발 메스꺼움 및 구토(CINV) 시장 규모는 앞으로 수년간 강력한 성장이 예상됩니다. 2029년까지 CAGR 7.5%로 확대되어 41억 9,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 맞춤형 의료, 구토방지제 진보, 원격 의료 및 원격 모니터링, 건강 공평성에 대한 노력에 기인합니다. 예측기간의 주요 동향에는 구토방지제의 병용요법, 지지요법 서비스, 디지털 헬스툴, 서바이버십 케어 등이 있습니다.

향후 5년간의 성장률 7.5%라는 예측은 지난 예측으로부터 0.1% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 상승은 인도나 이스라엘에서 조달되는 NK1 수용체 길항제나 5-HT3 억제제의 비용을 밀어 올리고, 치료의 부작용을 악화시키고, 구토방지제의 비용을 증가시킴으로써 미국 환자에게 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

암 이환율 증가가 화학요법 유발 메스꺼움 및 구토(CINV) 시장 확대의 원동력이 될 것으로 예측됩니다. 암의 증식은 신체의 특정 세포가 통제 할 수없는 성장을 이루고 신체의 다른 부위로 전이함으로써 발생합니다. 암 환자가 증가하는 가운데, 화학요법의 부작용인 CINV를 완화하기 위해, 보다 효과적이고 대상을 좁힌 제토요법의 개발이 서두르고 있습니다. 이와 같이 CINV의 관리에 대한 관심이 높아짐에 따라, 그 근본적인 메커니즘의 해명이 진행되고, 혁신적인 치료법이 만들어지고 있습니다. 예를 들어, 2023년 1월 현재 미국암협회(ACS)는 2023년 미국에서 신규 암 이환 환자수는 약 190만명(1일당 약 5,370명), 암 관련 사망자수는 60만 9,820명(1일당 약 1,670명)이라고 예측했습니다. 그 결과, 암의 유병률 증가가 화학요법 유발 메스꺼움 및 구토(CINV) 시장의 원동력이 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Chemotherapy-induced nausea and vomiting (CINV) is a condition characterized by the sensation of nausea and vomiting, often arising as a side effect of chemotherapy treatment. This common side effect can significantly impact the quality of life and treatment outcomes for many cancer patients. Fortunately, CINV can be effectively managed and treated through medications and lifestyle adjustments.

CINV presents in various forms, including injectables, oral medications, and transdermal patches. Injectables are chemical substances administered via injection to produce various therapeutic effects. Medications used for CINV management belong to different drug classes, such as 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids, and others. The risk of developing CINV varies, with emetogenic risks categorized into highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC), and low emetogenic chemotherapy (LEC). These treatments and medications are distributed through multiple channels, including CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies, and drug stores. They find application in various medical fields such as gynecology, urology, gastrointestinal surgery, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chemotherapy-induced nausea and vomiting (CINV) market research report is one of a series of new reports from The Business Research Company that provides chemotherapy-induced nausea and vomiting (CINV) market statistics, including chemotherapy-induced nausea and vomiting (CINV) industry global market size, regional shares, competitors with a chemotherapy-induced nausea and vomiting (CINV) market share, detailed chemotherapy-induced nausea and vomiting (CINV) market segments, market trends and opportunities and any further data you may need to thrive in the chemotherapy-induced nausea and vomiting (CINV) industry. This chemotherapy-induced nausea and vomiting (CINV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.92 billion in 2024 to $3.13 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.

The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $4.19 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.

The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of NK1 receptor antagonists and 5-HT3 inhibitors sourced from India and Israel, exacerbating treatment side effects and increasing antiemetic medication costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of cancer is set to drive the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the foreseeable future. The proliferation of cancer occurs when certain cells in the body undergo uncontrolled growth and spread to other parts of the body. With cancer cases on the rise, there is a growing impetus to develop more effective and targeted antiemetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on managing CINV has led to advancements in understanding its underlying mechanisms and the creation of innovative therapies. For example, as of January 2023, the American Cancer Society (ACS) anticipates around 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer-related deaths (about 1,670 deaths per day) in the United States for 2023. Consequently, the increasing prevalence of cancer will be a driving force behind the chemotherapy-induced nausea and vomiting (CINV) market.

The growth of the chemotherapy-induced nausea and vomiting (CINV) market is expected to be driven by the increasing favorable regulatory initiatives. Regulatory initiatives are actions undertaken by regulatory bodies to develop, enforce, or implement regulations. These initiatives are aimed at enhancing the prevention and management of chemotherapy-induced nausea and vomiting (CINV) by establishing guidelines and policies. For example, in October 2024, the U.S. Food and Drug Administration (FDA), a federal agency focused on public health protection, reported that in 2023, its Center for Drug Evaluation and Research (CDER) approved 55 new drugs specifically for chemotherapy-induced nausea and vomiting (CINV). As a result, the growing favorable regulatory initiatives are propelling the growth of the CINV market.

Major companies in the chemotherapy-induced nausea and vomiting (CINV) market are focusing on new product innovations, such as fixed intravenous antiemetics, to gain a competitive edge. A fixed intravenous antiemetic refers to a predetermined dose of medication delivered via IV to prevent or treat nausea and vomiting, commonly used in chemotherapy or post-surgery contexts. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical manufacturer, launched AKYNZEO I.V. in India, the first fixed intravenous antiemetic combination designed to prevent chemotherapy-induced nausea and vomiting (CINV). This product combines netupitant and palonosetron, addressing both acute and delayed phases of nausea and vomiting. It offers single-dose convenience, higher complete response rates, and improved quality of life for cancer patients. Clinical studies indicate it is especially effective for patients undergoing highly emetogenic chemotherapy.

In January 2022, Cumberland Pharmaceuticals Inc., a U.S.-based specialty pharmaceutical firm, acquired SANCUSO (granisetron transdermal patch) from Kyowa Kirin Inc. for $13.5 million. This acquisition granted Cumberland full control over the U.S. rights to SANCUSO, a chemotherapy-induced nausea and vomiting (CINV) drug. This included responsibility for marketing, promotion, distribution, manufacturing, and medical support operations related to the product. Kyowa Kirin Inc. is a U.S.-based subsidiary of Kyowa Kirin Co. Ltd. in Japan, a specialty pharmaceutical company that specializes in developing innovative medicines used for preventing CINV.

Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.

North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chemotherapy-induced nausea and vomiting (CINV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy-induced nausea and vomiting (CINV) market consists of revenues earned by entities by providing services such as pharmacologic therapy and nonpharmacologic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced nausea and vomiting (CINV) market also includes the sales of such as olanzapine, dexamethasone, cannabinoids, metoclopramide, promethazine and prochlorperazine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy-induced nausea and vomiting (cinv) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chemotherapy-induced nausea and vomiting (cinv) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chemotherapy-induced nausea and vomiting (cinv) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Characteristics

3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies

4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Growth Analysis And Strategic Analysis Framework

6. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segmentation

7. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Regional And Country Analysis

8. Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market

9. China Chemotherapy-Induced Nausea and Vomiting (CINV) Market

10. India Chemotherapy-Induced Nausea and Vomiting (CINV) Market

11. Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market

12. Australia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

13. Indonesia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

14. South Korea Chemotherapy-Induced Nausea and Vomiting (CINV) Market

15. Western Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market

16. UK Chemotherapy-Induced Nausea and Vomiting (CINV) Market

17. Germany Chemotherapy-Induced Nausea and Vomiting (CINV) Market

18. France Chemotherapy-Induced Nausea and Vomiting (CINV) Market

19. Italy Chemotherapy-Induced Nausea and Vomiting (CINV) Market

20. Spain Chemotherapy-Induced Nausea and Vomiting (CINV) Market

21. Eastern Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market

22. Russia Chemotherapy-Induced Nausea and Vomiting (CINV) Market

23. North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market

24. USA Chemotherapy-Induced Nausea and Vomiting (CINV) Market

25. Canada Chemotherapy-Induced Nausea and Vomiting (CINV) Market

26. South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market

27. Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) Market

28. Middle East Chemotherapy-Induced Nausea and Vomiting (CINV) Market

29. Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market

30. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Landscape And Company Profiles

31. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Other Major And Innovative Companies

32. Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market

34. Recent Developments In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market

35. Chemotherapy-Induced Nausea and Vomiting (CINV) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기